Our findings revealed a marked difference in PARP3 expression between AML samples and normal bone marrow controls (p < 0.05, Figure 1A,B), with markedly elevated PARP3 levels observed in intermediate- and high-risk AML subgroups (p < 0.05, Figure 1C). The gene discussed is PARP3; the disease is acute myeloid leukemia.